Division Announcements News

WashU Medicine researchers show pregnancy-based hepatitis C program improves access to curative treatment

Treatment increases were greatest among rural patients and those who delivered at regional hospitals across Missouri and southern Illinois

Madeline McCrary, MD (left); Laura Marks, MD, PhD; Jeannie Kelly, MD, MS; Megan Rose Curtis, MD, MS

Researchers at WashU Medicine have found that a health system–wide quality-improvement program can significantly increase access to hepatitis C (HCV) treatment for pregnant patients and may improve the chances that they complete therapy. In a recent study, the team evaluated HALT-C—short for hepatitis C antenatal linkage-to-care—a program designed to identify patients earlier in pregnancy, coordinate care across multiple sites, and offer treatment either during pregnancy or after delivery.

Their findings were published on November 4, 2026, in Obstetrics & Gynecology.

The study showed that after HALT-C was implemented, the percentage of eligible patients prescribed direct-acting antivirals by 6 months postpartum increased from 48.4% to 77.1%. Treatment completion also improved, rising from 21.0% to 54.3%. The greatest gains were seen among patients delivering at regional hospitals, where prescribing increased from 14.3% to 72.7%. Treatment prescriptiongains were also most pronounced among patients residing in rural regions, where completion rates increased from 23.8% to 90.0%. More than half of patients were treated via telemedicine. Among patients who attended a prenatal HCV appointment, 75% preferred treatment during pregnancy, and those treated antenatally were twice as likely to complete therapy as those who waited until after delivery.

Led by Madeline McCrary, MD, Assistant Professor of Medicine, HALT-C brought together WashU Medicine Division of Infectious disease physicians, pharmacists and care coordinators and Division of Maternal-Fetal Medicine & Ultrasound specialists to reduce barriers to treatment across a large health system serving both academic and regional sites. Although infant screening and overall perinatal transmission rates did not change significantly, notably no perinatal transmissions occurred among infants whose mothers received antenatal treatment.

The findings suggest that pregnancy may be an important window for initiating curative HCV therapy and that coordinated, patient-centered care models can help close longstanding gaps in treatment access. They also underscore the value of flexible care pathways, including telemedicine, especially for patients in rural or regional settings who may face barriers to postpartum follow-up. More broadly, the study offers a model that other health systems in Missouri and beyond could adapt to expand access for pregnant patients, while also informing future multicenter implementation studies.


McCrary LM, Marks LR, Kelly JC, Atkinson A, Elrod-Gallegos J, Kojima P, Werner P, Mullersman JL, Habrock-Bach T, Durkin MJ, Curtis MR. Hepatitis C Treatment Access With Implementation of an Antenatal Linkage-to-Care Bundle. Obstet Gynecol. 2026 Nov 4. doi: 10.1097/AOG.0000000000006458. Epub ahead of print. PMID: 42976312.